ABK Biomedical Raises $35M to Bring Visibility—and Precision—to the Future of Interventional Oncology
In a decisive move for the interventional oncology space, ABK Biomedical has closed an oversubscribed US$35 million Series D round, led by J.P. Morgan Life Sciences Private Capital. Longtime backers including F‑Prime, Santé Ventures, Eight Roads Ventures, and a strategic but undisclosed medical device player also participated. The fresh capital will underwrite the clinical operations…
